Welcome to BioReagent Hub Hotline:19920083827
产品资料来源于品牌方官网 yeasen.com  |  仅供选型参考,规格与库存以官方最新信息为准
品官方资料 · 来源可溯查看原始页面 ›
Vendor Tel:400-6111-883
Product data sheet PD-20605ES
Human Oxidized Low Density Lipoprotein (Human Ox-LDL) 人源氧化低密度脂蛋白 Human Oxidized Low Density Lipoprotein (Human Ox-LDL) 人源氧化低密度脂蛋白
Enquiry

Tell us your volume and application; we reply with a quote.

Start enquiry

Human Oxidized Low Density Lipoprotein (Human Ox-LDL) 人源氧化低密度脂蛋白

Scan for product
通用脂质代谢研究动脉粥样硬化研究受体介导内吞作用研究
Product no.20605ES Sizes2 options SourceYeasen · Official
Cat. No. 20605ES05
现货 $2,528.00 促$2,655.00
Qty 1
Enquire now
Enquire / bulk Compare

Specifications & Enquiry

Tick the specs you need to submit them together; or enquire one by one. Cat. numbers are carried into the RFQ.

Cat.No Spec Price Status
20605ES05 2 mg $2,528.00促$2,655.00 现货 Enquire
20605ES10 5× 2 mg $11,078.00促$11,655.00 现货 Enquire
Submit enquiry Price is on application; bulk sizes can be sampled on request.

Overview

Specifications

Brand翌圣生物 Yeasen
Cat.No20605ES
Specification蛋白纯度(Purity)>97%(琼脂糖凝胶电泳)蛋白浓度(Concentration)1.0~3.9 mg/mL(Lowry法)外观(Appearance)无色乳状液体缓冲液配方(Buffer Formulation)0.1 mM EDT
Origin翌圣生物科技(上海)股份有限公司
技术平台 通用
应用方法 脂质代谢研究应用 动脉粥样硬化研究应用 受体介导内吞作用研究应用
适用物种种属 人
检测方法 琼脂糖凝胶电泳 Lowry法 TBARS检测
生物特性参数 蛋白类型氧化低密度脂蛋白(天然) 表达/来源系统人血浆 应用脂质代谢研究;动脉粥样硬化研究;受体介导内吞作用研究
样本类型 血浆
技术参数 浓度1.0~3.9 mg/mL (Lowry法) 纯度>97% (琼脂糖凝胶电泳) 制剂配方0.1 mM EDTA-Na2 in PBS pH 7.4 外观无色乳状液体 氧化程度TBARS检测:Ox-LDL 20~26 nmol MDA/mg蛋白;起始LDL 0.1~0.5 nmol MDA/mg蛋白 储存条件2~8℃无菌避光保存,有效期6周,不可冻存
实验类型 通用通用

FAQ

Q:该产品与 20604 区别是什么?

A:该产品主要研究 LDL 在功能和代谢中的氧化作用;而 20604 主要研究乙酰化作用。

Q:该产品的缓冲液是多少?

A:10 μM CuSO4 的PBS 溶液。

Q:如何终止产品的氧化反应?

A:加入过量的 EDTA。

Q:该产品长期保存会出现少量沉淀,还可以使用吗?

A:这是正常现象。低速离心 1~2 min 去除沉淀物,即得到澄清液。

Documents & Citations

Published citations

  1. Xu H, She P, Zhao Z, Ma B, Li G, Wang Y. Duplex Responsive Nanoplatform with Cascade Targeting for Atherosclerosis Photoacoustic Diagnosis and Multichannel Combination Therapy. Adv Mater. 2023;35(21):e2300439. doi:10.1002/adma.202300439(IF:29.4)
  2. Zhang H, Ge S, Ni B, et al. Augmenting ATG14 alleviates atherosclerosis and inhibits inflammation via promotion of autophagosome-lysosome fusion in macrophages. Autophagy. 2021;17(12):4218-4230. doi:10.1080/15548627.2021.1909833(IF:16.016)
  3. Kai H, Wu Q, Yin R, et al. LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6. Front Cell Dev Biol. 2021;9:701628. Published 2021 Jul 9. doi:10.3389/fcell.2021.701628(IF:6.684)
  4. Tao J, Qiu J, Lu L, et al. ZBTB20 Positively Regulates Oxidative Stress, Mitochondrial Fission, and Inflammatory Responses of ox-LDL-Induced Macrophages in Atherosclerosis. Oxid Med Cell Longev. 2021;2021:5590855. Published 2021 Mar 9. doi:10.1155/2021/5590855(IF:6.543)
  5. Wang Y, Xu Z, Wang X, et al. Extracellular-vesicle containing miRNA-503-5p released by macrophages contributes to atherosclerosis. Aging (Albany NY). 2021;13(8):12239-12257. doi:10.18632/aging.103855(IF:5.682)
  6. Zhang Y, Xu X, Ma J, et al. Loss of CD226 protects apolipoprotein E-deficient mice from diet-induced atherosclerosis. Biochim Biophys Acta Mol Basis Dis. 2022;1868(9):166452. doi:10.1016/j.bbadis.2022.166452(IF:5.187)

Recommended reading

Related products

✉Email 💬Message 👤Member
↑Top